Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07782632Recruiting
Imaging scans to predict immunotherapy response in liver cancer
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hefei, AnhuiAges 18–75 - NCT06559761Recruiting
Imaging to predict liver cancer aggressiveness after surgery
This study looks at whether special scans can help doctors better predict how aggressive a person's liver cancer (hepatocellular carcinoma) will be, especially right after surgery. If you are planning to have surgery to remove the tumor as your first treatment, this trial might be a good fit.
Beijing, Beijing MunicipalityAges 18–80 - NCT06007729RecruitingPhase 2
A study of HS-20093 for head and neck cancer and other solid tumors
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
Hefei, AnhuiAges 18 years+ - NCT06563869RecruitingPhase 3
Sintilimab with chemo and growth factor before esophageal cancer surgery
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Nanjing, JiangsuAges 18–75 - NCT07768189RecruitingPhase 3
Testing CRB-701 for throat cancer that returned
This study tests an investigational drug called CRB-701 to see if it can help people with a certain type of throat cancer that has not responded to standard treatments. The trial compares CRB-701 to a doctor's choice of other available treatments.
Huntsville, AlabamaAges 18 years+ - NCT07773688Recruiting
Microscopy study of skin biopsy samples
This study uses a special microscope to look at skin biopsy samples in more detail. It may help doctors understand skin conditions better and improve future diagnoses.
Victor, New YorkAges Any age - NCT06575322Recruiting
Neoadjuvant therapy for head and neck cancer: effects on pain and mood
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
Guanzhou, GuangdongAges 18–80 - NCT07762885RecruitingPhase 3
Comparing skipping radiation after surgery for early-stage DCIS
This trial compares skipping radiation therapy after breast-conserving surgery for low- or intermediate-risk ductal carcinoma in situ (DCIS) – a very early, non-invasive breast cancer. It aims to see if omitting radiation is as effective as standard treatment while reducing side effects.
ShanghaiAges 40 years+ - NCT07762924RecruitingPhase 2
Skipping radiation for younger women with low-risk DCIS
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
ShanghaiAges Up to 40 years - NCT07762976RecruitingPhase 2
Tailoring chemo for nasopharyngeal cancer using EBV-DNA and MRI
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06581315Recruiting
Donafenib after surgery for high-risk liver cancer
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT05517135Recruiting
Personalized treatment for EBV-positive nasopharyngeal cancer
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
SingaporeAges 21–99 - NCT07756437Recruiting
Blood test for detecting bladder cancer DNA
This study is testing a simple blood test that looks for cancer DNA in your blood. The goal is to see if it can accurately detect muscle-invasive bladder cancer or upper tract urothelial cancer.
Ghent, East FlandersAges 18 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT07751341RecruitingPhase 2
New drug with chemotherapy for advanced esophageal cancer
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06344052RecruitingPhase 2
SP-002 with Vismodegib for Advanced Basal Cell Cancer
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06607107RecruitingPhase 2
Combination therapy for liver cancer beyond Milan criteria
This trial tests a combination of chemotherapy (mFOLFOX7) plus two targeted/immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer that has grown beyond standard transplant criteria. It aims to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07744932RecruitingPhase 2
Radiation plus drug combo for kidney cancer that has spread a little
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
Shijiazhuang, HebeiAges 18 years+ - NCT06611150RecruitingPhase 1
Chemo and radiation for advanced nasopharyngeal cancer
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
Guangzhou, GuangdongAges 18–70 - NCT06613581Recruiting
Home-based follow-up after colorectal cancer surgery
This trial tests whether patients can do their follow-up from home after surgery for colorectal cancer. It uses a smartphone app instead of hospital visits, aiming to make surveillance easier and less stressful.
Breda, North BrabantAges 21 years+ - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT07733180RecruitingPhase 2
Study of tislelizumab plus chemo for advanced esophageal cancer
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
Yokohama, KanagawaAges 18 years+ - NCT06624098Recruiting
Early TIPS for Advanced Liver Cancer with Vein Blockage
This study tests whether placing a small tube (TIPS) early in people with advanced liver cancer and a vein blockage helps their other treatments work better. It is for patients who are already taking lenvatinib and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.